New Delhi, May 12
Bharat Biotech’s Covaxin has received the drug regulatory nod for advance clinical trials on children aged between 2 and 18 years.
The subject expert committee of the Central Drug Standards Control Organisation (CDSCO) said the trials would be conducted on 525 children at various sites, including at AIIMS-New Delhi, AIIMS-Patna and Meditrina Institute of Medical Sciences, Nagpur. — TNS
Advertisement
×
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Combo
Yearly
Monthly
Already a Member? Sign In Now
Advertisement
Advertisement
Advertisement